Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity

Introduction: Ozempic (semaglutide) is a long-acting GLP-1 receptor agonist widely used to treat type II diabetes and obesity. Its mechanism of action includes stimulation of insulin secretion, inhibition of glucagon secretion, and delaying gastric emptying, which leads to lower blood glucose level...

Full description

Bibliographic Details
Published in:	Quality in Sport
Main Authors:	Agnieszka Głuszczyk, Jakub Plizga, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Agata Frańczuk, Michalina Grzelka, Julia Głoskowska, Katarzyna Kuleta, Patrycja Karkos
Format:	Article
Language:	English
Published:	Nicolaus Copernicus University in Toruń 2024-08-01
Subjects:	ozempic ozempic face semaglutide GLP-1 obesity
Online Access:	https://apcz.umk.pl/QS/article/view/53683

Similar Items

Ozempic (semaglutide) - review of pharmacological properties, mechanism of action and clinical applications
by: Anna Maria Koman, et al.
Published: (2024-07-01)

Dose-dependent erythema nodosum after initiation of semaglutide
by: Jeffrey Sobieraj, MD, et al.
Published: (2024-05-01)

Semaglutide and weight loss – a concern for diabetics and pharmaceuticals
by: Bushra Admani, et al.
Published: (2024-05-01)

Danuglipron – an innovate GLP agonist - literature short review
by: Agata Frańczuk, et al.
Published: (2024-08-01)

Semaglutide versus Tirzepatide - comparison of both drugs in treatment of diabetes type 2 and weight reduction
by: Arkadiusz Staroń, et al.
Published: (2024-08-01)

Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study
by: Onur Baser, et al.
Published: (2024-06-01)

The prevalence and consequences of support for off-label Ozempic prescriptions
by: Timothy Callaghan, et al.

Cosmetic Considerations of Semaglutide
by: Alaina Baggett, et al.
Published: (2025-10-01)

The Worldwide Problem of Obesity - Comparison of the Effectiveness of Pharmacological Treatment with Semaglutide and Tirzepatide in Reducing Body Weight
by: Karolina Garbino, et al.
Published: (2025-03-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

Health Beliefs and Obesity Bias as Determinants of Attitudes Toward the Rising Tides of GLP-1 Medications: Mounjaro and Ozempic
by: Al-Mahzoum K, et al.
Published: (2025-05-01)

The Upadacitinib - New Janus Kinase Inhibitor - Literature Review
by: Michalina Grzelka, et al.
Published: (2024-08-01)

The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study
by: Sara Alenzi, et al.
Published: (2024-08-01)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND)
by: Stav Brown, et al.
Published: (2024-09-01)

The Impact of E-Cigarettes and Tobacco Heating Systems on Health: A Review of Current Research
by: Jakub Plizga, et al.
Published: (2024-08-01)

Bempedoic acid – new agent in hiperlipidemia treatment – literature review
by: Agata Frańczuk, et al.
Published: (2024-08-01)

Semaglutide-induced fixed drug eruption
by: Sahithi Talasila, BS, et al.
Published: (2025-02-01)

Ozempic (Glucagon-like peptide 1 receptor agonist) in social media posts: Unveiling user perspectives through Reddit topic modeling
by: Seraphina Fong, et al.
Published: (2024-12-01)

Rimegepant - a breakthrough drug for migraine treatment - literature review
by: Katarzyna Kuleta, et al.
Published: (2024-08-01)

Nordic walking – the healthiest sport ever? – A review
by: Angelika Szpulak, et al.
Published: (2024-09-01)

Evolving Body Contouring Strategies for Patients After Massive Weight Loss: Insights from Bariatric and Pharmacologic Interventions
by: Salvatore Giordano, et al.
Published: (2025-05-01)

A Global Misuse of Semaglutide for Cosmetic Weight Loss in Non-diabetic Young Population, an FDA Public Database and Google Trends Data Analysis
by: Nahid Sabah aldin Saber, et al.
Published: (2025-08-01)

Natural Peptides Versus Semaglutide: A Safer Approach to Obesity Management
by: Muhammad Affan Abid, et al.
Published: (2025-09-01)

The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review
by: Marta Wolszczak, et al.
Published: (2025-06-01)

Advances in migraine treatment - a review
by: Katarzyna Słychan, et al.
Published: (2024-08-01)

Retatrutide - revolutionary recently developed GLP agonist - literature review
by: Patrycja Brzozowska, et al.
Published: (2024-07-01)

Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes
by: Jessica Duncan, et al.
Published: (2025-09-01)

A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice
by: Jonathan D. Douros, et al.
Published: (2025-10-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

From needles to pills: oral GLP-1 therapy enters the obesity arena
by: Gaetano Santulli
Published: (2025-10-01)

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01)

AI‐Driven De Novo Design of Ultra Long‐Acting GLP‐1 Receptor Agonists
by: Ting Wei, et al.
Published: (2025-10-01)

GLP-1 Receptor Agonists: Therapeutic Benefits in Renal Function, Cardiovascular Risk, and Physical Activity - A Systematic Review
by: Łukasz Karaban, et al.
Published: (2025-05-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonists in T1DM Patients
by: Deene Mohandas, et al.
Published: (2023-02-01)

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

GLP-1 RA for cardiometabolic risk reduction in obesity – How do we best describe benefit and value?
by: Sant Kumar, et al.
Published: (2024-06-01)

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
by: Yoshinori Ozeki, et al.
Published: (2022-09-01)

Methods of surfactant administration in newborn. Literature review
by: Julia Głoskowska, et al.
Published: (2024-09-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review
by: Serene Lee, et al.
Published: (2024-11-01)